Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CEACAM5/CD66e Antibody (C66/1260) - IHC-Prediluted, Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP248043
Description
CEACAM5/CD66e Monoclonal specifically detects CEACAM5/CD66e in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
CEACAM5/CD66e | |
Monoclonal | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
CEACAM5 | |
Purified human CEACAM5/CD66e protein (Uniprot: P06731) | |
7 mL | |
Cancer, Cellular Markers, Immunology | |
1048 | |
Human | |
Purified |
Immunohistochemistry (Paraffin) | |
C66/1260 | |
Immunohistochemistry-Paraffin | |
Carcinoembryonic antigen, carcinoembryonic antigen-related cell adhesion molecule 5, CD66e antigen, CEACD66e, DKFZp781M2392, Meconium antigen 100 | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This monoclonal antibody reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbladder, urachus, salivary gland, ovary, and endocervix. | |
Store at 4C. | |
IgG2b κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Product Content Correction